MORE►
MI Cancer Seek
David Halbert, founder, chairman, and CEO of Caris Life Sciences. [Courtesy: Caris]
North Texas’ Caris Life Sciences Eyes $5.3B Valuation in Its Nasdaq IPO
by David Seeley | Jun 10, 2025
The Irving-based leader in precision oncology—which has raised $1.86 billion since 2018—plans to raise as much as $423.5 million when it goes public on the Nasdaq Global Select Market under the ticker symbol CAI.
by Lance Murray |
Nov 6, 2024
Caris said MI Cancer Seek will be used as a companion diagnostic to identify cancer patients who may benefit from treatment with targeted therapies.
MORE►
